Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pluristem to Raise $30 Million from China's Innovative Medical

publication date: Oct 27, 2016

Pluristem Therapeutics, an Israeli regenerative medicine company, signed a term sheet for a $30 million investment from China's Innovative Medical Management. Pluristem develops placental cells using a proprietary, three-dimensional bioreactor to expand cells. The company plans to start a Phase III trial of its PLX-PAD cells for critical limb ischemia in Japan and Europe next year. Innovative Medical, which is active in life science, owns three large hospitals in China along with other life science investments. More details....

Stock Symbols: (NSDQ/Tel Aviv: PSTI) (SHZ: 002173)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital